Advertisement
UK markets closed
  • FTSE 100

    8,155.72
    -49.17 (-0.60%)
     
  • FTSE 250

    21,067.68
    -166.48 (-0.78%)
     
  • AIM

    784.13
    -3.54 (-0.45%)
     
  • GBP/EUR

    1.1866
    -0.0009 (-0.08%)
     
  • GBP/USD

    1.2910
    -0.0037 (-0.29%)
     
  • Bitcoin GBP

    51,865.00
    +2,298.30 (+4.64%)
     
  • CMC Crypto 200

    1,329.35
    -1.54 (-0.11%)
     
  • S&P 500

    5,505.00
    -39.59 (-0.71%)
     
  • DOW

    40,287.53
    -377.49 (-0.93%)
     
  • CRUDE OIL

    80.25
    -2.57 (-3.10%)
     
  • GOLD FUTURES

    2,402.80
    -53.60 (-2.18%)
     
  • NIKKEI 225

    40,063.79
    -62.56 (-0.16%)
     
  • HANG SENG

    17,417.68
    -360.73 (-2.03%)
     
  • DAX

    18,171.93
    -182.83 (-1.00%)
     
  • CAC 40

    7,534.52
    -52.03 (-0.69%)
     

Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions

GERMANTOWN, Md., June 13, 2024--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL.

Breakfast and refreshments will be provided beginning at 9:15 am ET on Sunday, June 23, 2024, in advance of a business update presentation from management scheduled to begin, at 10:00 am ET. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company’s website at www.senseonics.com.

In-person attendance for the event requires advanced registration. Please email Hannah Jeffrey at hannah@gilmartinir.com by June 21, 2024, to register.

ADVERTISEMENT

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613143680/en/

Contacts

Senseonics Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com